Vosoritide's first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to ...

WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic ...

A radiologist study finds that artificial intelligence assistance improves fracture detection accuracy in children with osteogenesis imperfecta.

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia Published Jun 4, 2024 7 ...

Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) Published Jul 2, 2024 4:05pm EDT ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that positive data from the CANOPY clinical program evaluating VOXZOGO® (vosoritide) in children with achondroplasia and other genetic ...

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia ...

Investigator-Sponsored Oral Presentation Vosoritide Increases Growth Velocity in Hypochondroplasia: Phase 2 Trial Results Oral Session: O03 Thursday, March 14, 2024, 1:30 - 3 p.m. ET About VOXZOGO ...

The authors studied 24 children with hypochondroplasia. Half were female and 22 out of 24 had the p.Asn540Lys variant in the fibroblast growth factor receptor 3 (FGFR3) gene.